Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
Divya Goel1★★ Corresponding author
- 1Department of Pharmacology, MMIMSR, Mullana, Ambala, Haryana, India.
CORRESPONDENCE
Divya Goel
Department of Pharmacology, MMIMSR, Mullana, Ambala, Haryana, India.
Volume 5, Issue 1 · pp. 76–78 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.124435
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Tuberculosis (TB) is among the most common infectious diseases and continues as a major global health problem. The scenario is worsened by the emergence and spread of multiple drug-resistant tuberculosis (MDR-TB) and extensive drug-resistant tuberculosis (XDR-TB). Cure rates are high for drug sensitive strains of Myobacterium tuberculosis if treatment protocols are adhered to, but treatment of MDR-TB and extensive drug drug-resistant strains is virtually impossible. The treatment of MDR-TB and XDR-TB relies on the drugs, which are less potent, more toxic and more costly and have to be administered for the longer duration. No new drug had come in to market for last 40 years, but the emergence of MDR-TB and XDR-TB has spurred interest in the development of novel drugs. For the effective treatment outcome, there is a dire need of new drugs with a different mechanism of action that can tackle both drug sensitive as well as drug-resistant strains. Bedaquiline is one such new drug with unique mechanism of action. Food and Drug Administration has approved bedaquiline for MDR-TB in December 2012. This article reviews the available evidence of efficacy and safety of bedaquiline.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Goel, D. (2014). Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis. Journal of Pharmacology and Pharmacotherapeutics, 5(1), 76–78. https://doi.org/10.4103/0976-500X.124435